Pro-Pharmaceuticals, Inc. & Mount Sinai School of Medicine Announce New Liver Fibrosis Research Collaboration

NEWTON, Mass.--(BUSINESS WIRE)--Pro-Pharmaceuticals, Inc. (OTC: PRWP), the leading developer of Galectin therapeutics to treat cancer and fibrosis, today announced it has entered into a new research collaboration with Mount Sinai School of Medicine to evaluate in pre-clinical models, the anti-fibrotic effects of several of the Company’s novel, Galectin-targeting compounds.

MORE ON THIS TOPIC